Schaumburg, IL, United States
Schaumburg, IL, United States

Time filter

Source Type

MENLO PARK, Calif., March 2, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share early clinical and pre-clinical data at the 2017 American Academy of Dermatology (AAD) Annual Meeting,...


News Article | February 15, 2017
Site: www.marketwired.com

SCHAUMBURG, IL--(Marketwired - Feb 14, 2017) - Hand rashes can be frustrating, especially when the cause of your rash is unknown. Was it a new brand of hand soap? Eczema? Or just really dry skin? According to dermatologists from the American Academy of Dermatology, it could be any of these things and more. Hand rashes, they say, commonly occur because of something you touched or something happening inside your body. "There are many reasons for hand rashes," said Melissa Piliang, MD, FAAD, a board-certified dermatologist at the Cleveland Clinic in Ohio. "The most common cause is eczema, but some hand rashes may have an allergic cause. Sometimes, an allergy can develop after years of touching the same things daily without a problem, like your wedding ring, skin care products or foods such as fish, garlic or citrus fruits." To help prevent a hand rash, Dr. Piliang recommends the following tips: 1. Wear task-appropriate, protective gloves. Harsh chemicals, such as dyes and detergents, and even water can irritate your skin and cause a hand rash. To protect your hands, wear gloves while gardening or doing housework. Remember to replace gloves that develop a hole, and never wear wet gloves. 2. Wear warm gloves in cold temperatures. Cold weather can be very drying to your hands, making it a good idea to wear warm, insulated gloves or mittens outdoors. 3. Wash your hands without irritating them. Since soap and water can remove oils from your skin, wash your hands with warm water and a mild cleanser, such as a beauty bar or moisturizing liquid. 4. Apply moisturizer often and generously. Apply it immediately after washing your hands and multiple times throughout the day. For the best results, use a product that contains glycerin or petrolatum. "Thousands of things can cause a hand rash, yet most hand rashes look a lot alike to the untrained eye," said Dr. Piliang. "If you get a hand rash, see a board-certified dermatologist to help identify the cause and prevent it from becoming painful or disabling." Treatment plans for hand rashes may include a non-prescription cream or lotion or prescription medication. If a dermatologist suspects that an allergy is the cause, he or she may recommend an allergy skin test called patch testing. These tips are demonstrated in "How to Prevent and Treat Hand Rashes," a video posted to the AAD website and YouTube channel. This video is part of the AAD's "Video of the Month" series, which offers tips people can use to properly care for their skin, hair and nails. A new video in the series posts to the AAD website and YouTube channel each month. Headquartered in Schaumburg, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 18,000 physicians worldwide, the AAD is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, contact the AAD at 1-888-462-DERM (3376) or aad.org. Follow the AAD on Facebook (American Academy of Dermatology), Twitter (@AADskin), or YouTube (AcademyofDermatology). To view in a media-rich format, go to: aad.new-media-release.com/2017/hand_rash/


News Article | February 15, 2017
Site: www.prweb.com

Connecticut Dermatology Group (CDG) is proud and excited to welcome back to the team, Dr. Sang H. Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest physician-directed skincare center. “It is with considerable pleasure to welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. Steven A. Kolenik III. “She embodies everything we strive for at CDG. She was and will continue to be a sought-after provider due to her compassion, demeanor, outstanding clinical skills and attention to detail.” Dr. Kim received her undergraduate degree from Yale University, where she graduated with a bachelor’s degree in biology. She earned her doctorate from New York University School of Medicine and then completed a dermatology residency at the University of Chicago as chief resident. She then completed a fellowship in dermatopathology before joining Connecticut Dermatology Group in 2006. In 2013, Dr. Kim and her family relocated to Charlotte, North Carolina where she worked in the dermatology department of Mecklenburg Medical Group, a large interdisciplinary medical practice. She and her family moved back to Connecticut in 2016. Dr. Kim, who will see patients at CDG’s locations in Norwalk and Stamford, says: “I am thrilled to be rejoining my CDG family. Their level of passion for providing the most advanced skin care is unmatched and makes working here rewarding for me and a great medical experience for patients. I am looking forward to seeing some familiar faces and meeting new ones.” Dr. Kim is a board certified dermatologist and is a fellow of the American Academy of Dermatology. She has had extensive training in all aspects of adult and pediatric dermatology. Her training in dermatopathology provides her with a unique vantage point in her approach to dermatologic conditions. Dr. Kim’s special interests include detecting and treating skin cancer, evaluating rashes and skin growths, and performing cosmetic laser procedures. Dr. Kim will begin seeing patients on February 28th, 2017. You can book an appointment with her now by calling 203-810-4151 or scheduling an appointment online. About Connecticut Dermatology Group Connecticut Dermatology Group (CDG) is a leader in dermatology services in Connecticut. Since it’s founding in 1964, CDG has provided comprehensive skin care to tens of thousands in Connecticut through its Norwalk, Milford, and Stamford offices. CDG is Fairfield County’s largest physician-directed skincare center providing medical and surgical care, as well as state-of-the-art cosmetic and aesthetician services. CDG has been designated as a national dermatological testing center to conduct clinical trials for new and upcoming medical and cosmetic services. Managing Partner, Dr. Steven A. Kolenik III has been peer nominated as 2016 Top Doctor in Fairfield County by Castle Connolly and a 2017 Top Doctor in Connecticut by Connecticut Magazine. Dr. Kolenik III has completed over 20,000 Mohs procedures.


News Article | February 15, 2017
Site: www.prweb.com

In the past decade, platelet-rich plasma (PRP) treatments have become common in orthopedics, but you may soon enjoy more benefits of this innovative treatment on your skin. According to the National Center for Biotechnology Information (NCBI), PRP treatment is effective in a variety of dermatological applications. But this is not the only dermatology trend expected to be big in 2017. “I’m excited at what’s coming in 2017, including an impressive method of facial rejuvenation,” said Dr. Isaac. “PRP injections stimulate your skin's production of collagen, which results in glowing, youthful skin. As popular as I think these injections are, there are other trends I’m also looking forward to.” One trend poised to go viral is facial treatments with unique ingredients, such as charcoal, wine, or even snail secretions. These are modern twists on traditional substances that have long been used around the world for improving skin. If these ingredients don't appeal to you, then you might be relieved to know that several of the country’s most well-known cosmetic treatments will continue to rise in popularity, such as Botox®, which is expected to become even more popular among men of all ages. “As medicine continues evolving, patients looking to fight the effects of aging will try innovative products, as long as they are safe and effective,” said Dr. Isaac. “And although these cutting-edge treatments may be very effective, there are still plenty of patients who remain loyal to the traditionally popular ones, such as the neuromodulators like Botox® and dermal fillers like Juvederm® and Restylane®. The ingredients in those and other injectables are always improving to ensure more effective and faster results; plus, new injectable fillers are being developed with their own unique benefits.” Another facial rejuvenation treatment expected to get more attention is NovaThreads®, a nonsurgical facelift that uses dissolvable sutures to lift and tighten the skin. For those more interested in body sculpting, there is good news, as well, as CoolSculpting® looks poised to continue its meteoric rise in the new year. To find out more about body contouring, please visit: http://www.MI-Skin.com/Body-Contouring-Skin-Tightening. “I always look forward to the new year because of the incoming products that I can use to help my patients achieve their goals – and 2017 is no different. In fact, with some of the new products and innovations on the horizon, it might be more exciting than usual,” Dr. Isaac said. “However, regardless of which treatment you’re considering, be sure to do your due diligence and choose a board-certified, experienced doctor; that’s more important than which product or treatment you choose.” Dr. Melda Isaac is a board-certified dermatologist located in Washington, DC. Her practice, MI Skin Dermatology Center, is a comprehensive skin care practice that offers the latest and most advanced state-of-the-art technology to the skin’s appearance. Dr. Isaac obtained her medical degree from Penn State University and completed her dermatology residency at George Washington University. She is an active member of the American Academy of Dermatology, the American Society for Dermatologic Surgery, the Women’s Dermatologic Society, the American Society for Laser Medicine and Surgery, and the Washington, DC, Dermatologic Society. You can find out more about Dr. Isaac and MI Skin Dermatology Center at http://MI-Skin.com/contact


News Article | March 3, 2017
Site: www.24-7pressrelease.com

TARZANA, CA, March 03, 2017-- Castle Dermatology Institute and dermatologist , Dr. Ghasri, are now offering liquid facelifts with Sculptra. A liquid facelift can be an excellent alternative to the conventional facelift for those who are interested in facial rejuvenation but are not yet ready for or need a full lift. A liquid facelift uses injectable treatments such as Sculptra to soften early signs of aging and restore youthful contours without resorting to more invasive, surgical treatments.With the right injectable treatments and facial fillers , a non-surgical liquid facelift can be used to contour, lift, and sculpt various areas of the face to restore youth without ever making a single incision. The goal is to create subtle, beautiful results while reducing lines, wrinkles, creases, folds, and expression lines.Dr. Ghasri can use a liquid facelift with Sculptra to address many facial complaints, including:- Drooping features, such as jowls and brows- Improve sunken eyes, under eye bags, and dark circles under the eyes- Create smoother contours on the nose- Add volume to the cheeks and temples- Create fuller, more voluptuous lips- Restore lost volume to sunken areasSculptra is a PLLA collagen stimulator that works deep inside the dermis to stimulate collagen production and restore the youthful contours of the skin's structure and volume. The effects can last up to two years. Patients can combine a Sculptra facelift with other dermal fillers and injectables to customize their results. Other options include Juvederm, Radiesse, Botox, Dysport injections, and Ultherapy.About Drs. Peyman and Pedram GhasriDr. Peyman Ghasri is a graduate of UCLA and UC Irvine. He is a diplomate of the American Board of Dermatology, a fellow of the American Academy of Dermatology, a member of the American Society of Mohs Surgery, and a fellow of the American Society of Dermatologic Surgery. He is a popular lecturer, and his work is widely published in a variety of peer-reviewed journals.Dr. Pedram Ghasri is a top dermatologist. A board-certified dermatologist, Dr. Ghasri graduated from UCLA and UC Irvine and is a board-certified dermatologist with an extensive body of work in peer-reviewed journals.Castle Dermatology Institute accepts patients in Tarzana, Encino, and the surrounding cities, including Studio City , Woodland Hills, Reseda, Sherman Oaks, Calabasas , Northridge, North Hills, and other cities in San Fernando Valley.Visit http://www.castlederm.com for more information.


RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced that the results from RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its Phase 2b clinical trial of VT-1161 in approximately 260 patients with onychomycosis of the toenail, will be presented in a late-breaking research forum at the American Academy of Dermatology 2017 Annual Meeting, to be held March 3-7, 2017, in Orlando, Florida. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally-administered inhibitor of fungal CYP51. Amir Tavakkol, Ph.D., Viamet’s Chief Development Officer, will give a presentation titled “Efficacy and Safety Outcomes from a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Four Oral VT-1161 Regimens in the Treatment of Patients with Moderate-Severe Distal-Lateral Subungual Onychomycosis (DLSO),” summarizing key efficacy and safety data from the study. The presentation will take place during the Late-Breaking Research: Clinical Trials session at the conference, scheduled for Saturday, March 4 from 9:00 AM — 11:00 AM (EST). About VT-1161 VT-1161 is a potent and selective, orally-administered inhibitor of fungal CYP51 which recently completed Phase 2b clinical trials for the treatment of onychomycosis, or fungal nail infection, and recurrent vulvovaginal candidiasis (RVVC), a common and difficult to treat infection in women. VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. In preclinical studies, VT-1161 has demonstrated broad-spectrum activity against both dermatophytes and Candida species, including those species that cause onychomycosis and RVVC. Given the clinical and preclinical profile of VT-1161, the Company believes that it may avoid the side effects that limit the use of current oral antifungal therapies, such as liver toxicity and drug-drug interactions. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to VT-1161 for the treatment of RVVC. Created under the Generating Antibiotics Incentives Now (GAIN) Act of 2012, QIDP designation provides significant incentives for the development of innovative antimicrobial agents like VT-1161, including the potential for priority review by the FDA, and a five-year extension of marketing exclusivity under the Hatch-Waxman Act. Fast Track designation from the FDA supports the development and expedited review of new therapies with a goal to deliver important new drugs to patients earlier in order to fill unmet medical needs. About the RENOVATE Study RENOVATE was a randomized, double-blind, placebo-controlled, clinical trial of VT-1161 in patients with distal-lateral subungual onychomycosis (DLSO) of the large toenail. The trial evaluated two dose levels of VT-1161 (300 mg and 600 mg) administered once weekly for either 10 or 22 weeks following an initial two week, once-daily loading dose period. The trial enrolled 259 patients with 25-75% DLSO involvement of the large toenail at baseline at 32 sites throughout the United States. At baseline, mean DLSO involvement of the large toenail was 46% and the average number of toenails affected was 4.6 across the trial arms. The primary efficacy endpoint was complete cure of the large toenail at week 48, a composite endpoint that requires both complete clinical cure and negative mycology. Patients were also evaluated for complete cure at week 60. About Onychomycosis Onychomycosis, a fungal infection that primarily involves the nail, nail bed and surrounding tissues, is an extremely common infection, affecting approximately 32 million individuals in the United States. The infection is characterized by deformation, discoloration, thickening and splitting of the nail, as well as separation of the nail plate from the nail bed. Damage to the nail can also result in pain when walking, limiting ambulation. The unsightly appearance of the infected nail and the perception that there is an active and contagious infection is a significant concern for many patients. Onychomycosis can also be a significant medical issue for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities. In these patients, the infected nail can serve as an entry point for bacterial infection, which can in turn lead to serious complications such as tissue necrosis and amputation. About Viamet (www.viamet.com) Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs. This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet’s business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc., VPS-3, Inc. and Viamet Pharmaceuticals (Bermuda), Ltd. The Viamet group of companies are based in the Research Triangle Park region of North Carolina, USA and Hamilton, Bermuda.


News Article | March 2, 2017
Site: globenewswire.com

MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV, will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology, or AAD, in Orlando, Florida. Stephen Tyring, M.D., Ph.D., is scheduled to present “Results From Phase II Study of Nitric Oxide-Releasing SB206 Once Daily Administration Show Favorable Efficacy and Safety in Genital Warts” on Saturday, Mar. 4. Dr. Tyring was one of the investigators in this clinical trial and is a board-certified dermatologist at the Dermatological Association of Texas in Houston and professor of dermatology at the University of Texas Health Science Center at Houston McGovern Medical School. “The data from this clinical trial demonstrated the very real potential of Novan’s topical nitric oxide-releasing product candidate, SB206, against genital warts,” said Dr. Tyring. “Patients treated with SB206 12% once-daily experienced a statistically significant benefit in wart clearance as compared to those treated with vehicle, with low rates of application site adverse events and treatment discontinuations. If approved, SB206 could be a novel approach and an important alternative to current treatment paradigms that are often painful.” Abstract Number: 5220 Title: “Results From Phase II Study of Nitric Oxide-Releasing SB206 Once Daily Administration Show Favorable Efficacy and Safety in Genital Warts” Authors: S. Tyring, V. Almendarez, J. Scoggin Presenter: Stephen Tyring, M.D., Ph.D. Date and Time: Saturday, Mar. 4, 2017, 9:50 – 10:00 a.m. Eastern Time Session: F056, Late-breaking Research: Clinical Trials HPV refers to a large family of double-stranded DNA viruses that induce abnormal growths on the skin or mucosal surfaces. HPV affects nearly 80 million Americans, and an estimated 14 million new cases of the virus are reported each year, according to the Centers for Disease Control and Prevention, or CDC. There are over 100 subtypes of the virus, characterized as low-risk or high-risk based on their cancer-causing potential. The virus is typically transmitted via direct skin-to-skin contact through disruptions in the normal skin barrier. All warts are caused by HPV, including genital and perianal warts, common warts and plantar warts. Genital warts are among the world's most common sexually transmitted diseases. Genital warts are usually flesh-colored growths that can be raised, flat or cauliflower-shaped and are typically found on the surface of the external genitalia or in and around the anus. In males, they can appear on the surface of the penis and scrotum, and in females inside the vagina or on the cervix. Genital warts carry a substantial psychosocial burden due to the shame and embarrassment related to having a sexually transmitted disease as well as the inconvenience and discomfort of current treatment modalities. Current treatment options for genital warts consist of ablative procedures that cut, burn or freeze the warts but do not address the underlying viral infection, and there are no currently approved oral or topical prescription products indicated for the treatment of genital warts with a direct anti-viral mechanism of action. Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market. For more information, visit the Company’s website at www.Novan.com. This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates, expected performance of our product candidates, publication and presentation of our trial results in the medical community and future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, uncertainties and risks in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research or trials; the lengthy and unpredictable nature of the U.S. Food and Drug Administration’s drug approval process; whether we will be able to obtain additional funding when needed; and other risks and uncertainties described in our prospectus dated Sept. 20, 2016, filed with the Securities and Exchange Commission, or SEC, in our quarterly report filed with the SEC on Form 10-Q for the three months ended Sept. 30, 2016, and in any subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.


News Article | March 2, 2017
Site: globenewswire.com

MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV, will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology, or AAD, in Orlando, Florida. Stephen Tyring, M.D., Ph.D., is scheduled to present “Results From Phase II Study of Nitric Oxide-Releasing SB206 Once Daily Administration Show Favorable Efficacy and Safety in Genital Warts” on Saturday, Mar. 4. Dr. Tyring was one of the investigators in this clinical trial and is a board-certified dermatologist at the Dermatological Association of Texas in Houston and professor of dermatology at the University of Texas Health Science Center at Houston McGovern Medical School. “The data from this clinical trial demonstrated the very real potential of Novan’s topical nitric oxide-releasing product candidate, SB206, against genital warts,” said Dr. Tyring. “Patients treated with SB206 12% once-daily experienced a statistically significant benefit in wart clearance as compared to those treated with vehicle, with low rates of application site adverse events and treatment discontinuations. If approved, SB206 could be a novel approach and an important alternative to current treatment paradigms that are often painful.” Abstract Number: 5220 Title: “Results From Phase II Study of Nitric Oxide-Releasing SB206 Once Daily Administration Show Favorable Efficacy and Safety in Genital Warts” Authors: S. Tyring, V. Almendarez, J. Scoggin Presenter: Stephen Tyring, M.D., Ph.D. Date and Time: Saturday, Mar. 4, 2017, 9:50 – 10:00 a.m. Eastern Time Session: F056, Late-breaking Research: Clinical Trials HPV refers to a large family of double-stranded DNA viruses that induce abnormal growths on the skin or mucosal surfaces. HPV affects nearly 80 million Americans, and an estimated 14 million new cases of the virus are reported each year, according to the Centers for Disease Control and Prevention, or CDC. There are over 100 subtypes of the virus, characterized as low-risk or high-risk based on their cancer-causing potential. The virus is typically transmitted via direct skin-to-skin contact through disruptions in the normal skin barrier. All warts are caused by HPV, including genital and perianal warts, common warts and plantar warts. Genital warts are among the world's most common sexually transmitted diseases. Genital warts are usually flesh-colored growths that can be raised, flat or cauliflower-shaped and are typically found on the surface of the external genitalia or in and around the anus. In males, they can appear on the surface of the penis and scrotum, and in females inside the vagina or on the cervix. Genital warts carry a substantial psychosocial burden due to the shame and embarrassment related to having a sexually transmitted disease as well as the inconvenience and discomfort of current treatment modalities. Current treatment options for genital warts consist of ablative procedures that cut, burn or freeze the warts but do not address the underlying viral infection, and there are no currently approved oral or topical prescription products indicated for the treatment of genital warts with a direct anti-viral mechanism of action. Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market. For more information, visit the Company’s website at www.Novan.com. This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates, expected performance of our product candidates, publication and presentation of our trial results in the medical community and future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, uncertainties and risks in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research or trials; the lengthy and unpredictable nature of the U.S. Food and Drug Administration’s drug approval process; whether we will be able to obtain additional funding when needed; and other risks and uncertainties described in our prospectus dated Sept. 20, 2016, filed with the Securities and Exchange Commission, or SEC, in our quarterly report filed with the SEC on Form 10-Q for the three months ended Sept. 30, 2016, and in any subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.


News Article | March 2, 2017
Site: globenewswire.com

MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV, will be presented during a Late-breaking Research forum at the 2017 Annual Meeting of the American Academy of Dermatology, or AAD, in Orlando, Florida. Stephen Tyring, M.D., Ph.D., is scheduled to present “Results From Phase II Study of Nitric Oxide-Releasing SB206 Once Daily Administration Show Favorable Efficacy and Safety in Genital Warts” on Saturday, Mar. 4. Dr. Tyring was one of the investigators in this clinical trial and is a board-certified dermatologist at the Dermatological Association of Texas in Houston and professor of dermatology at the University of Texas Health Science Center at Houston McGovern Medical School. “The data from this clinical trial demonstrated the very real potential of Novan’s topical nitric oxide-releasing product candidate, SB206, against genital warts,” said Dr. Tyring. “Patients treated with SB206 12% once-daily experienced a statistically significant benefit in wart clearance as compared to those treated with vehicle, with low rates of application site adverse events and treatment discontinuations. If approved, SB206 could be a novel approach and an important alternative to current treatment paradigms that are often painful.” Abstract Number: 5220 Title: “Results From Phase II Study of Nitric Oxide-Releasing SB206 Once Daily Administration Show Favorable Efficacy and Safety in Genital Warts” Authors: S. Tyring, V. Almendarez, J. Scoggin Presenter: Stephen Tyring, M.D., Ph.D. Date and Time: Saturday, Mar. 4, 2017, 9:50 – 10:00 a.m. Eastern Time Session: F056, Late-breaking Research: Clinical Trials HPV refers to a large family of double-stranded DNA viruses that induce abnormal growths on the skin or mucosal surfaces. HPV affects nearly 80 million Americans, and an estimated 14 million new cases of the virus are reported each year, according to the Centers for Disease Control and Prevention, or CDC. There are over 100 subtypes of the virus, characterized as low-risk or high-risk based on their cancer-causing potential. The virus is typically transmitted via direct skin-to-skin contact through disruptions in the normal skin barrier. All warts are caused by HPV, including genital and perianal warts, common warts and plantar warts. Genital warts are among the world's most common sexually transmitted diseases. Genital warts are usually flesh-colored growths that can be raised, flat or cauliflower-shaped and are typically found on the surface of the external genitalia or in and around the anus. In males, they can appear on the surface of the penis and scrotum, and in females inside the vagina or on the cervix. Genital warts carry a substantial psychosocial burden due to the shame and embarrassment related to having a sexually transmitted disease as well as the inconvenience and discomfort of current treatment modalities. Current treatment options for genital warts consist of ablative procedures that cut, burn or freeze the warts but do not address the underlying viral infection, and there are no currently approved oral or topical prescription products indicated for the treatment of genital warts with a direct anti-viral mechanism of action. Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market. For more information, visit the Company’s website at www.Novan.com. This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates, expected performance of our product candidates, publication and presentation of our trial results in the medical community and future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, uncertainties and risks in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research or trials; the lengthy and unpredictable nature of the U.S. Food and Drug Administration’s drug approval process; whether we will be able to obtain additional funding when needed; and other risks and uncertainties described in our prospectus dated Sept. 20, 2016, filed with the Securities and Exchange Commission, or SEC, in our quarterly report filed with the SEC on Form 10-Q for the three months ended Sept. 30, 2016, and in any subsequent filings with the SEC. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.


News Article | February 15, 2017
Site: www.prweb.com

Our culture cherishes youth. Youth is associated with innovation, passion, and well-being. People are searching for ways to maintain their energy and beauty as the years pile on. “Aging is a natural part of life that holds many benefits. On average, people become happier and more content with maturity. But aging has some cons, such as bodily pain and undesired looks. Nowadays, medicine can help people maintain the beauty of their youth as they get older,” says Dr. Suzanne Friedler with Advanced Dermatology PC. One skin issue of particular concern for men and women alike are age spots. “Age spots, or Lentigines, are small patches of light brown or black skin. They are harmless blemishes that appear with age, usually after the 40-year mark. They appear on areas that are consistently exposed to ultra violet light from the sun, such as the face, back of the hands, shoulders, forearms and upper back,” says Dr. Frielder. What causes age spots and who gets them? According to Dr. Friedler, “When an area of the skin is exposed to excessive UV light, those skin cells will produce more melanin, the pigment that gives skin the dark look. In young peoples’ skin, new cells regenerate rapidly to replace the damaged cells. However, this process slows down in older people and these damaged cells clump together and form these brown or black patches.” Dr. Friedler also notes that people with fair skin develop age spots more often since their skin is more susceptible to damage from UV light. Are age spots cancerous? “Before engaging in any treatment, the patient should consult a physician. It’s possible that these dark patches are cancerous cells rather than benign spots of excess melanin. A trained physician will provide the proper diagnosis.” Treatment options for Age spots Creams: Creams can be prescribed or bought over-the-counter. They work by bleaching the damaged area and slowly removing the color. The creams use hydroquinone with or without retinoids, such as tretinoin. This bleaching process takes months to complete. “It’s crucial that people apply sunscreen to the treatment area during this period, since these bleaching creams can make the skin cells more sensitive to damage from UV light,” adds Dr. Friedler. Lasers: Lasers can target specific pigment cells (melanocytes) in the skin and leave the surrounding tissue unharmed. This process is quick and the effects are immediate. Other laser treatments resurface the skin by removing the damaged cells and reveal the healthy cells beneath. Both laser treatments are highly effective. Microneedling: This treatment involves causing micro-injuries to the damaged cells with tiny needles. The body responds by producing new cells to heal over the damaged area, thus blocking the brown skin cells. Several treatments may be required to get the best results. Chemical Peel: This process involves applying a patch of chemicals to the damaged cells. These chemicals burn off the top layer of cells and reveal the healthy cells beneath. Dr. Friedler stresses not to worry about any ill effects, “chemical peels not only remove the damaged cells, but also promote healthy collagen production.” Cryosurgery: This treatment is prescribed if the physician suspects that the spots could be cancerous. It involves applying liquid nitrogen to the damaged cells, which freezes and kills them. Dermabrasion: This treatment involves sanding off the outer layers of damaged skin to reveal the healthy cells beneath. Despite the slew of treatment options, Dr. Friedler stresses the importance of prevention as the best treatment. Wearing sunscreen throughout the year, even in the winter, will reduce the likelihood of developing age spots. Always make sure you buy a broad-spectrum sunscreen that protects against both UVA and UVB rays with an SPF of at least 15.” Suzanne J. Friedler, M.D. F.A.A.D., is a board certified fellow of the American Academy of Dermatology, with expertise in many areas of medical and cosmetic dermatology. She has been with Advanced Dermatology PC since 2002. Advanced Dermatology P.C. and the Center for Laser and Cosmetic Surgery (New York & New Jersey) is one of the leading dermatology centers in the nation with 18 locations in New York and New Jersey, offering highly experienced physicians in the fields of cosmetic and laser dermatology as well as plastic surgery and state-of-the-art medical technologies. http://www.advanceddermatologypc.com.

Loading American Academy of Dermatology collaborators
Loading American Academy of Dermatology collaborators